Skip to main content

Table 2 SA-1: patient characteristics of the PS-matched subgroup

From: Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study

 

CCT (n = 91)

Without CCT (n = 91)

Standardized differencea

Number or mean (SD)a

(%)a

Number or mean (SD)a

(%)a

Age (years)

     

  ≤ 58

47

(52)

44

(48)

0.066

  > 58

44

(48)

47

(52)

 

Gender

     

 Female

5

(5)

3

(3)

0.107

 Male

86

(95)

88

(97)

 

Residency

     

 Non-north

66

(73)

70

(77)

0.101

 North

25

(27)

21

(23)

 

Comorbidity

     

 Without

79

(87)

83

(91)

0.141

 Withb

12

(13)

8

(9)

 

BMI (kg/m2)

     

  ≤ 18.5

20

(22)

14

(15)

0.170

  > 18.5

71

(78)

77

(85)

 

Drinking

     

 No

13

(14)

15

(16)

0.061

 Yes

78

(86)

76

(84)

 

Smoking

     

 No

10

(11)

10

(11)

0

 Yes

81

(89)

81

(89)

 

Grade

     

 Poorly

28

(31)

23

(25)

0.123

 Well/moderately differentiated

63

(69)

68

(75)

 

Tumor location

     

 Upper

46

(51)

44

(48)

 

 Middle

32

(35)

35

(39)

0.068

 Lower

13

(14)

12

(13)

0.032

Tumor size (cm)

     

  ≤ 5 cm

38

(42)

43

(47)

0.111

  > 5 cm

53

(58)

48

(53)

 

Clinical T-stage

     

 T1–T2

10

(11)

9

(10)

0.036

 T3–T4

81

(89)

82

(90)

 

Clinical N-stage

     

 N0

9

(10)

8

(9)

0.038

 N1–N2

82

(90)

83

(91)

 

Clinical stage

     

 II

11

(12)

10

(11)

0.034

 III

80

(88)

81

(89)

 

Reason for no surgery

     

 Without contraindication

87

(96)

87

(96)

0

 With contraindication

4

(4)

4

(4)

 

RT modality

     

 3DCRT

6

(7)

3

(3)

0.152

 IMRT

85

(93)

88

(97)

 

Use of PET

     

 No

34

(37)

36

(40)

0.045

 Yes

57

(63)

55

(60)

 

RT break

     

  ≤ 1 week

69

(76)

70

(77)

0.026

  > 1 week

22

(24)

21

(23)

 

RT dose

     

 Low

23

(25)

22

(24)

0.025

 High

68

(75)

69

(76)

 

Induction chemotherapy

     

 Without

87

(96)

86

(95)

0.051

 With

4

(4)

5

(5)

 
  1. 3DCRT, three-dimensional radiotherapy; BMI, Body Mass Index; CCT, consolidative chemotherapy; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; PET, positron emission tomography; RT, radiotherapy; SD, standard deviation
  2. aRounded
  3. bModified Carlson comorbidity score ≥ 1